All companies
Visit website
PDX BIOTECH
OperatingPDX BIOTECH LLC
Healthcare · Biotech · Founded 2019
Rapid test for periodontal disease
Post-money valuation ⓘ
$32.2M
As of Dec 2022 · from PDX BIOTECH Security Units 1 · pre-money + amount raised, not a traded price
Total raised
$143,716
Across 1 round since 2022
Latest share price
$20.00
PDX BIOTECH Security Units 1 offering price
Financials
FY2020–FY2022 · from SEC filings · hover any figure for its source$32K
−$768
2020
$37K
−$16K
2021
$104K
−$300K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
FY2022
Income statement
Revenue
$31,675
$37,000
$104,000
Cost of goods sold
$16,934
$19,999
$60,000
Gross margin
47%
46%
42%
Net income
-$768
-$16,487
-$300,000
Taxes paid
$0
$0
$0
Balance sheet
Cash
$45
$3,103
$54,000
Accounts receivable
$0
$0
$0
Total assets
$4,081
$6,630
$208,000
Short-term debt
$0
$0
$27,000
Long-term debt
$0
$0
$0
Total liabilities
$0
$0
$27,000
Other
Headcount
—
10
10
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$32.2M
post-money
PDX BIOTECH Security Units 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $143.7K / $1.1MInvestors 35Post-money $32.2M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 1 of 4 annual reports (FY2022–FY2025)
35 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001941155Share price $20.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.